227 related articles for article (PubMed ID: 15264185)
1. Enhanced anticoagulant activity of enoxaparin in patients with ESRD as measured by thrombin generation time.
Brophy DF; Martin EJ; Gehr TW; Carr ME
Am J Kidney Dis; 2004 Aug; 44(2):270-7. PubMed ID: 15264185
[TBL] [Abstract][Full Text] [Related]
2. Antifactor Xa activity correlates to thrombin generation time, platelet contractile force and clot elastic modulus following ex vivo enoxaparin exposure in patients with and without renal dysfunction.
Brophy DF; Martin EJ; Best AM; Gehr TW; Carr ME
J Thromb Haemost; 2004 Aug; 2(8):1299-304. PubMed ID: 15304034
[TBL] [Abstract][Full Text] [Related]
3. Thrombin generation time is a novel parameter for monitoring enoxaparin therapy in patients with end-stage renal disease.
Brophy DF; Martin EJ; Gehr TW; Best AM; Paul K; Carr ME
J Thromb Haemost; 2006 Feb; 4(2):372-6. PubMed ID: 16420568
[TBL] [Abstract][Full Text] [Related]
4. Plasma levels of enoxaparin oligosaccharides, antifactor-Xa and thrombin generation in patients undergoing haemodialysis.
Batt TJ; Lincz LF; Prasad R; Patel RP; Shastri M; Lioufas N; Smith AG; Jose MD
Blood Coagul Fibrinolysis; 2020 Mar; 31(2):152-159. PubMed ID: 31990754
[TBL] [Abstract][Full Text] [Related]
5. The pharmacokinetics of enoxaparin do not correlate with its pharmacodynamic effect in patients receiving dialysis therapies.
Brophy DF; Carr ME; Martin EJ; Venitz J; Gehr TW
J Clin Pharmacol; 2006 Aug; 46(8):887-94. PubMed ID: 16855073
[TBL] [Abstract][Full Text] [Related]
6. Are low-molecular-weight heparins appropriately dosed in patients with CKD stage 3 to 5?
Yildirim T; Kocak T; Buyukasik Y; Yilmaz R; Altun B; Erdem Y; Arici M
Blood Coagul Fibrinolysis; 2012 Dec; 23(8):700-4. PubMed ID: 23135378
[TBL] [Abstract][Full Text] [Related]
7. Monitoring Enoxaparin with Antifactor Xa Levels in Obese Patients.
Lee YR; Vega JA; Duong HN; Ballew A
Pharmacotherapy; 2015 Nov; 35(11):1007-15. PubMed ID: 26598093
[TBL] [Abstract][Full Text] [Related]
8. Correlation of antifactor Xa concentrations with renal function in patients on enoxaparin.
Chow SL; Zammit K; West K; Dannenhoffer M; Lopez-Candales A
J Clin Pharmacol; 2003 Jun; 43(6):586-90. PubMed ID: 12817521
[TBL] [Abstract][Full Text] [Related]
9. The pharmacokinetics of subcutaneous enoxaparin in end-stage renal disease.
Brophy DF; Wazny LD; Gehr TW; Comstock TJ; Venitz J
Pharmacotherapy; 2001 Feb; 21(2):169-74. PubMed ID: 11213853
[TBL] [Abstract][Full Text] [Related]
10. Safety and efficacy of single bolus anticoagulation with enoxaparin for chronic hemodialysis. Results of an open-label post-certification study.
Klingel R; Schwarting A; Lotz J; Eckert M; Hohmann V; Hafner G
Kidney Blood Press Res; 2004; 27(4):211-7. PubMed ID: 15273423
[TBL] [Abstract][Full Text] [Related]
11. Anti-metastatic effect of a non-anticoagulant low-molecular-weight heparin versus the standard low-molecular-weight heparin, enoxaparin.
Mousa SA; Linhardt R; Francis JL; Amirkhosravi A
Thromb Haemost; 2006 Dec; 96(6):816-21. PubMed ID: 17139378
[TBL] [Abstract][Full Text] [Related]
12. [The risk of bleeding associated with low molecular weight heparin in patients with renal failure].
Lai S; Barbano B; Cianci R; Gigante A; Di Donato D; Asllanaj B; Dimko M; Mariotti A; Morabito S; Pugliese F
G Ital Nefrol; 2010; 27(6):649-54. PubMed ID: 21132647
[TBL] [Abstract][Full Text] [Related]
13. Comparison of the anticoagulant intensities of fondaparinux and enoxaparin in the Organization to Assess Strategies in Acute Ischemic Syndromes (OASIS)-5 trial.
Anderson JA; Hirsh J; Yusuf S; Johnston M; Afzal R; Mehta SR; Fox KA; Budaj A; Eikelboom JW
J Thromb Haemost; 2010 Feb; 8(2):243-9. PubMed ID: 19943881
[TBL] [Abstract][Full Text] [Related]
14. Once versus twice daily injection of enoxaparin for thromboprophylaxis in bariatric surgery: effects on antifactor Xa activity and procoagulant microparticles. A randomized controlled study.
Steib A; Degirmenci SE; Junke E; Asehnoune K; Figier M; Pericard C; Rohr S; Letessier E; Brunaud L; Vix M; Zobairi F; Grunebaum L; Toti F
Surg Obes Relat Dis; 2016; 12(3):613-621. PubMed ID: 26686309
[TBL] [Abstract][Full Text] [Related]
15. Bioactivity of enoxaparin in critically ill patients with normal renal function.
Gouya G; Palkovits S; Kapiotis S; Madl C; Locker G; Stella A; Wolzt M; Heinz G
Br J Clin Pharmacol; 2012 Nov; 74(5):806-14. PubMed ID: 23227470
[TBL] [Abstract][Full Text] [Related]
16. A hypothesis-generating study to evaluate platelet activity in diabetics with chronic kidney disease.
Brophy DF; Martin RJ; Gehr TW; Carr ME
Thromb J; 2005 Mar; 3(1):3. PubMed ID: 15796773
[TBL] [Abstract][Full Text] [Related]
17. Comparative analysis of procoagulatory activity of haemodialysis, haemofiltration and haemodiafiltration with a polysulfone membrane (APS) and with different modes of enoxaparin anticoagulation.
Klingel R; Schaefer M; Schwarting A; Himmelsbach F; Altes U; Uhlenbusch-Körwer I; Hafner G
Nephrol Dial Transplant; 2004 Jan; 19(1):164-70. PubMed ID: 14671052
[TBL] [Abstract][Full Text] [Related]
18. Lobectomy and postoperative thromboprophylaxis with enoxaparin improve blood hypercoagulability in patients with localized primary lung adenocarcinoma.
Papageorgiou C; Vandreden P; Marret E; Bonnet F; Robert F; Spyropoulos A; Galea V; Elalamy I; Hatmi M; Gerotziafas GT
Thromb Res; 2013 Nov; 132(5):584-91. PubMed ID: 24094602
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of a Heparin-Calibrated Antifactor Xa Assay for Measuring the Anticoagulant Effect of Oral Direct Xa Inhibitors.
Beyer J; Trujillo T; Fisher S; Ko A; Lind SE; Kiser TH
Clin Appl Thromb Hemost; 2016 Jul; 22(5):423-8. PubMed ID: 26842561
[TBL] [Abstract][Full Text] [Related]
20. Comparison of the effect of fondaparinux and enoxaparin on thrombin generation during in-vitro clotting of whole blood and platelet-rich plasma.
Gerotziafas GT; Depasse F; Chakroun T; Van Dreden P; Samama MM; Elalamy I
Blood Coagul Fibrinolysis; 2004 Mar; 15(2):149-56. PubMed ID: 15091002
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
